This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nulens, E.
Right arrow Articles by Goubau, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nulens, E.
Right arrow Articles by Goubau, P.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, July 2000, p. 536-539, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Reactivity to p52 and CM2 Recombinant Proteins in Primary Human Cytomegalovirus Infection with a Microparticle Agglutination Assay

Eric Nulens,1 Monique Bodéus,1 Fabrizio Bonelli,2 Antonio Soleti,2 and Patrick Goubau1,*

Department of Microbiology, Unit of Virology, Université Catholique de Louvain, UCL 3055, 1200 Brussels, Belgium,1 and DiaSorin Diagnostics s.r.l., 13040 Sallugia (Vercelli), Italy2

Received 29 November 1999/Returned for modification 8 February 2000/Accepted 17 March 2000

We evaluated the reactivities of sera against p52 and CM2 recombinant antigens of human cytomegalovirus (HCMV), coated on microparticles, for the differentiation of primary HCMV infection from an established infection. Two different test formats of the CMV Multiplex Copalis assay were evaluated. The 214 serum samples tested were immunoglobulin M (IgM) positive or equivocal by our reference assay. Reactivities against p52 and CM2 antigens were tested for sera from 37 patients with a well-documented seroconversion within the preceding 3 months (119 serum specimens), 31 patients known to have had a seroconversion at least 8 months earlier (31 serum specimens), and 57 patients without a documented seroconversion (64 serum specimens). The assay had a sensitivity for the detection of a primary infection of 70 or 86% by the first test format and a sensitivity of 88 or 94% by the second test format, according to the criteria used to indicate a primary infection by this test. A good correlation of the results of the assay with our in-house avidity index was found. The specificity of the assay warrants further evaluation. With IgM-positive sera, the assay was not sufficiently specific to make a distinction between a primary infection and an established infection.


* Corresponding author. Mailing address: Department of Microbiology, Unit of Virology, Université Catholique de Louvain, Clos Chapelle aux Champs 30, UCL 3055, 1200 Brussels, Belgium. Phone: 32 27 64 34 20. Fax: 32 27 64 31 63. E-mail: goubau{at}mblg.ucl.ac.be.


Clinical and Diagnostic Laboratory Immunology, July 2000, p. 536-539, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Lang, D., Vornhagen, R., Rothe, M., Hinderer, W., Sonneborn, H.-H., Plachter, B. (2001). Cross-Reactivity of Epstein-Barr Virus-Specific Immunoglobulin M Antibodies with Cytomegalovirus Antigens Containing Glycine Homopolymers. CVI 8: 747-756 [Abstract] [Full Text]